Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers

Journal of Acquired Immune Deficiency Syndromes

Volumn 33, Issue 1, 2003, Pages 47-55

  Noonan, Douglas M ^a   Gringeri, Alessandro ^b   Meazza, Raffaella ^a   Rosso, Ombretta ^a   Mazza, Stefania ^c   Muça Perja, Myrvet ^b   Le Buanec, Hélène ^d   Accolla, Roberto S ^c,e   Albini, Adriana ^a   Ferrini, Silvano ^a,f  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d SORBONNE UNIVERSITÉ   (France)

^e Advanced Biotechnology Center   (Italy)

^f CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

Author keywords

Epitope mapping; HIV; Humoral response; Kaposi sarcoma; Tat; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ISA 051; TRANSACTIVATOR PROTEIN;

ADULT; AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; VACCINATION;

EID: 0038034441     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200305010-00008     Document Type: Article

References (50)

1. Gatignol A, Jeang K-T. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. In Jeang K-T, ed. HIV-1: molecular biology and pathogenesis. San Diego: Academic Press, 2000:209-27.
2. Noonan DM, Albini A. From the outside in: extracellular activities of HIV Tat. In Jeang K-T, ed. HIV-1: molecular biology and pathogenesis. San Diego: Academic Press, 2000:229-50.
3. Brake D, Debouck C, Biesecker G. Identification of an Arg-GlyAsp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990;111:1275-81.
4. Barillari G, Gendelman R, Gallo RC, et al. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90:7941-5.
5. Vogel BE, Lee S-J, Hildebrand A, et al. A novel integrin specificity exemplified by binding of the αvβ5 integrin to the basic domain of the HIV tat protein and vitronectin. J Cell Biol 1993; 121:461-8.
6. Subramanyam M, Gutheil WG, Bachovchin WW, et al. Mechanism of HIV-1 Tat induced inhibition of antigen-specific T cell responsiveness. J Immunol 1993;150:2544-53.
7. Ott M, Emiliani S, Van LC, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997;275:1481-5.
8. Albini A, Soldi R, Giunciuglio D, et al. The angiogenesis induced by HIV-1 Tat is mediated by the flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-5.
9. Ganju RK, Munshi N, Nair BC, et al. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998;72:6131-7.
10. Morini M, Benelli R, Giunciuglio D, et al. Kaposi's sarcoma cells of different etiologic origins respond to HIV-Tat through the Flk1/KDR (VEGFR-2): relevance in AIDS-KS pathology. Biochem Biophys Res Commun 2000;273:267-71.
11. Montaldo F, Maffe A, Morini M, et al. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol 2000;184:246-54.
12. Albini A, Ferrini S, Benelli R, et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998;95:13153-8.
13. Ghezzi S, Noonan DM, Aluigi MG, et al. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem Biophys Res Commun 2000;270:992-6.
14. Benelli R, Barbero A, Ferrini S, et al. Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: implications for Tat-mediated pathogenesis. J Infect Dis 2000;182:1643-51.
15. Hegg CC, Hu S, Peterson PK, et al. Beta-chemokines and human immunodeficiency virus type-1 proteins evoke intracellular calcium increases in human microglia. Neuroscience 2000;98:191-9.
16. de Paulis A, De Palma R, Di Gioia L, et al. Tat protein is an HIV-1-encoded β-chemokine homolog that promotes migration and up-regulates CCR3 expression on human FcεRI(+) cells. J Immunol 2000;165:7171-9.
17. Xiao H, Neuveut C, Tiffany HL, et al. Selective CXCR4 antagonism by tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000;97:11466-71.
18. Secchiero P, Zella D, Capitani S, et al. Extracellular HIV-1 Tat protein up-regulates the expression of surface CXC-chemokine receptor 4 in resting CD4+ T cells. J Immunol 1999;162:2427-31.
19. Huang L, Bosch I, Hofmann W, et al. Tat protein induces human immunodeficiency virus type I (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 1998;72:8952-60.
20. Cohen SS, Li C, Ding L, et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 1999;96:10842-7.
21. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995;375:497-500.
22. Zagury D, Lachgar A, Chams V, et al. Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95:3851-6.
23. Re MC, Furlini G, Vignoli M, et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:408-16.
24. van Baalen C, Pontesilli O, Huisman RC, et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997;78:1913-8.
25. Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998;1: 282-92.
26. Re MC, Vignoli M, Furlini G, et al. Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 2001;21:81-9.
27. Demirhan I, Chandra A, Mueller F, et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 2000;3:137-43.
28. Demirhan I, Chandra A, Hasselmayer O, et al. Intercellular traffic of human immunodeficiency virus type 1 transactivator protein defined by monoclonal antibodies. FEBS Lett 1999;445:53-6.
29. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia [see comments]. Nature 2000;407:386-90.
30. Jeang K-T. HIV-1 Tat: structure and function. In Myers, Korber, Foley, Jeang, et al., eds. Human retroviruses and AIDS 1996: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 1996. Available at: http://hivweb.lanl.gov.
31. Goldstein G. HIV-1 tat protein as a potential AIDS vaccine. Nat Med 1996;1:960-4.
32. Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6Pinfection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999;5:643-50.
33. Pauza CD, Trivedi P, Wallace M, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000;97:3515-9.
34. Gallo RC. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine. Proc Natl Acad Sci USA 1999;96:8324-6.
35. Le Buanec H, Lachgar A, Bizzini B, et al. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Biomed Pharmacother 1998;52:431-5.
36. Gringeri A, Santagostino E, Muca-Perja M, et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV1-infected patients. J Hum Virol 1998;1:293-8.
37. Gringeri A, Santagostino E, Muca-Perja M, et al. Tat toxoid as a component of a preventive vaccine in seronegative subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:371-5.
38. Tosi G, Meazza R, De Lerma Barbaro A, et al. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. Eur J Immunol 2000;30:1120-6.
39. Wright CM, Felber BK, Paskalis H, et al. Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 1986;234:988-92.
40. Tosi G, De Lerma Barbaro A, D'Agostino A, et al. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. Eur J Immunol 2000;30:19-28.
41. Frankel AD, Bredt DS, Pabo CO. Tat protein from human immunodeficiency virus forms a metal-linked dimer. Science 1988;240: 70-3.
42. Rice AP, Chan F. Tat protein of human immunodeficiency virus type 1 is a monomer when expressed in mammalian cells. Virology 1991;185:451-4.
43. Demirhan I, Chandra A, Hasselmayer O, et al. Detection of distinct patterns of anti-tat antibodies in HIV-infected individuals with or without Kaposi's sarcoma. J Acquir Immune Defic Syndr 1999;22: 364-8.
44. Wrenger S, Hoffmann T, Faust J, et al. The N-terminal structure of HIV-1 Tat is required for suppression of CD26-dependent T cell growth. J Biol Chem 1997;272:30283-8.
45. Proost P, Struyf S, Schols D, et al. Truncation of macrophagederived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction. J Biol Chem 1999;274:3988-93.
46. Gutheil WG, Subramanyam M, Flentke GR, et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994;91:6594-8.
47. Boykins RA, Mahieux R, Shankavaram UT, et al. Cutting edge: a short polypeptide domain of HIV-1-Tat protein mediates pathogenesis. J Immunol 1999;163:15-20.
48. Tähtinen M, Ranki A, Valle SL, et al. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Biomed Pharmacother 1997;51:480-7.
49. Addo MM, Altfeld M, Rosenberg ES, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001;98:1781-6.
50. Bayer P, Kraft M, Ejchart A, et al. Structural studies of HIV-1 Tat protein. J Mol Biol 1995;247:529-35.